Who
Kory James Wentworth
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Entrada Therapeutics; Principal Accounting Officer, bluebird bio.
In numbers
- Trades disclosed
- 145
- Buys
- 0
- Sells
- 42
- Bought
- $0
- Sold
- $2.5M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Jan 2018
- Last trade
- 2 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $12K1,733 at $7.14 | filing |
| 2 Sep 2026filed 3 Sep 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $12K1,733 at $7.14 | filing |
| 1 Apr 2026filed 2 Apr 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K2,500 at $12.95 | filing |
| 1 Apr 2026filed 2 Apr 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K2,500 at $12.95 | filing |
| 10 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $148K11,388 at $13.02 | filing |
| 10 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $148K11,388 at $13.02 | filing |
| 9 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K5,089 at $13.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $66K5,089 at $13.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $98K7,988 at $12.25 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $98K7,988 at $12.25 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $67K5,712 at $11.76 | filing |
| 3 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $67K5,712 at $11.76 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $34K2,939 at $11.66 | filing |
| 2 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $34K2,939 at $11.66 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,600 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,600 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,600 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,600 at $0.00 | filing |
| 21 Nov 2025filed 24 Nov 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Sold | $89K8,910 at $9.98 | filing |
| 2 Sep 2025filed 4 Sep 2025 | TRDA Entrada TherapeuticsBiotechnology | SEC FORM 4 Code F | $9,4161,734 at $5.43 | filing |
News
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45TRDA · manilatimes.net · 14 Oct 2026Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyTRDA · manilatimes.net · 14 Oct 2026Comparing Black Diamond Therapeutics (NASDAQ:BDTX) & Entrada Therapeutics (NASDAQ:TRDA)TRDA · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Kory James Wentworth; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.